SNT-317 (omigapil) in Congenital Muscular Dystrophies
Santhera, a Swiss pharmaceutical company, released financial updates for 2008 with forecast on its pharmaceutical focus for next year. Omigapil is a drug licensed by Santhera for treatment in the CMDs.
Preclinical work is ongoing internally in preparation of the clinical Phase II/III development. External clinical development (clinical trials) has been postponed to support Santhera’s current focus on the core programs. The EMEA and FDA have both granted orphan drug designation to omigapil in the 2 most common subtypes of CMD.